Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers.

Harmeier A, Obermueller S, Meyer CA, Revel FG, Buchy D, Chaboz S, Dernick G, Wettstein JG, Iglesias A, Rolink A, Bettler B, Hoener MC.

Eur Neuropsychopharmacol. 2015 Nov;25(11):2049-61. doi: 10.1016/j.euroneuro.2015.08.011. Epub 2015 Aug 20.

PMID:
26372541
2.

Preface to cognitive enhancement.

Kantak KM, Wettstein JG.

Handb Exp Pharmacol. 2015;228:v. No abstract available.

PMID:
26317138
3.

Closing thoughts for cognitive enhancement.

Kantak KM, Wettstein JG.

Handb Exp Pharmacol. 2015;228:451-9. doi: 10.1007/978-3-319-16522-6_16.

PMID:
25977093
4.

"Domain gauges": A reference system for multivariate profiling of brain fMRI activation patterns induced by psychoactive drugs in rats.

Bruns A, Mueggler T, Künnecke B, Risterucci C, Prinssen EP, Wettstein JG, von Kienlin M.

Neuroimage. 2015 May 15;112:70-85. doi: 10.1016/j.neuroimage.2015.02.032. Epub 2015 Feb 25.

PMID:
25724758
5.

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.

Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M, Harrison AC, Paehler A, Funk C, Gloge A, Schneider M, Parrott NJ, Polonchuk L, Niederhauser U, Morairty SR, Kilduff TS, Vieira E, Kolczewski S, Wichmann J, Hartung T, Honer M, Borroni E, Moreau JL, Prinssen E, Spooren W, Wettstein JG, Jaeschke G.

J Pharmacol Exp Ther. 2015 Apr;353(1):213-33. doi: 10.1124/jpet.114.222463. Epub 2015 Feb 9.

PMID:
25665805
6.

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

Jaeschke G, Kolczewski S, Spooren W, Vieira E, Bitter-Stoll N, Boissin P, Borroni E, Büttelmann B, Ceccarelli S, Clemann N, David B, Funk C, Guba W, Harrison A, Hartung T, Honer M, Huwyler J, Kuratli M, Niederhauser U, Pähler A, Peters JU, Petersen A, Prinssen E, Ricci A, Rueher D, Rueher M, Schneider M, Spurr P, Stoll T, Tännler D, Wichmann J, Porter RH, Wettstein JG, Lindemann L.

J Med Chem. 2015 Feb 12;58(3):1358-71. doi: 10.1021/jm501642c. Epub 2015 Feb 2.

PMID:
25565255
7.

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.

Scharf SH, Jaeschke G, Wettstein JG, Lindemann L.

Curr Opin Pharmacol. 2015 Feb;20:124-34. doi: 10.1016/j.coph.2014.11.004. Epub 2014 Dec 2. Review.

PMID:
25488569
8.

Homer1/mGluR5 activity moderates vulnerability to chronic social stress.

Wagner KV, Hartmann J, Labermaier C, Häusl AS, Zhao G, Harbich D, Schmid B, Wang XD, Santarelli S, Kohl C, Gassen NC, Matosin N, Schieven M, Webhofer C, Turck CW, Lindemann L, Jaschke G, Wettstein JG, Rein T, Müller MB, Schmidt MV.

Neuropsychopharmacology. 2015 Mar 13;40(5):1222-33. doi: 10.1038/npp.2014.308.

9.

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L.

JAMA Psychiatry. 2014 Jun;71(6):637-46. doi: 10.1001/jamapsychiatry.2014.163.

PMID:
24696094
10.

The CRTC1-SIK1 pathway regulates entrainment of the circadian clock.

Jagannath A, Butler R, Godinho SIH, Couch Y, Brown LA, Vasudevan SR, Flanagan KC, Anthony D, Churchill GC, Wood MJA, Steiner G, Ebeling M, Hossbach M, Wettstein JG, Duffield GE, Gatti S, Hankins MW, Foster RG, Peirson SN.

Cell. 2013 Aug 29;154(5):1100-1111. doi: 10.1016/j.cell.2013.08.004.

11.

Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.

Michalon A, Bruns A, Risterucci C, Honer M, Ballard TM, Ozmen L, Jaeschke G, Wettstein JG, von Kienlin M, Künnecke B, Lindemann L.

Biol Psychiatry. 2014 Feb 1;75(3):189-97. doi: 10.1016/j.biopsych.2013.05.038. Epub 2013 Jul 30.

PMID:
23910948
12.

Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome.

Martínez-Cué C, Martínez P, Rueda N, Vidal R, García S, Vidal V, Corrales A, Montero JA, Pazos Á, Flórez J, Gasser R, Thomas AW, Honer M, Knoflach F, Trejo JL, Wettstein JG, Hernández MC.

J Neurosci. 2013 Feb 27;33(9):3953-66. doi: 10.1523/JNEUROSCI.1203-12.2013.

13.

Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone.

Morairty SR, Revel FG, Malherbe P, Moreau JL, Valladao D, Wettstein JG, Kilduff TS, Borroni E.

PLoS One. 2012;7(7):e39131. doi: 10.1371/journal.pone.0039131. Epub 2012 Jul 2.

14.

Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine.

Revel FG, Meyer CA, Bradaia A, Jeanneau K, Calcagno E, André CB, Haenggi M, Miss MT, Galley G, Norcross RD, Invernizzi RW, Wettstein JG, Moreau JL, Hoener MC.

Neuropsychopharmacology. 2012 Nov;37(12):2580-92. doi: 10.1038/npp.2012.109. Epub 2012 Jul 4.

15.

Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.

Revel FG, Moreau JL, Gainetdinov RR, Ferragud A, Velázquez-Sánchez C, Sotnikova TD, Morairty SR, Harmeier A, Groebke Zbinden K, Norcross RD, Bradaia A, Kilduff TS, Biemans B, Pouzet B, Caron MG, Canales JJ, Wallace TL, Wettstein JG, Hoener MC.

Biol Psychiatry. 2012 Dec 1;72(11):934-42. doi: 10.1016/j.biopsych.2012.05.014. Epub 2012 Jun 16.

PMID:
22705041
16.

A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.

Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, Metzler V, Chaboz S, Groebke Zbinden K, Galley G, Norcross RD, Tuerck D, Bruns A, Morairty SR, Kilduff TS, Wallace TL, Risterucci C, Wettstein JG, Hoener MC.

Mol Psychiatry. 2013 May;18(5):543-56. doi: 10.1038/mp.2012.57. Epub 2012 May 29.

PMID:
22641180
17.

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L.

Neuron. 2012 Apr 12;74(1):49-56. doi: 10.1016/j.neuron.2012.03.009.

18.

Imaging trait anxiety in high anxiety F344 rats: Focus on the dorsomedial prefrontal cortex.

Prinssen EP, Nicolas LB, Klein S, Grundschober C, Lopez-Lopez C, Kessler MS, Bruns A, von Kienlin M, Wettstein JG, Moreau JL, Risterucci C.

Eur Neuropsychopharmacol. 2012 Jun;22(6):441-51. doi: 10.1016/j.euroneuro.2011.11.001. Epub 2011 Dec 6.

PMID:
22153786
19.

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.

Alberati D, Moreau JL, Lengyel J, Hauser N, Mory R, Borroni E, Pinard E, Knoflach F, Schlotterbeck G, Hainzl D, Wettstein JG.

Neuropharmacology. 2012 Feb;62(2):1152-61. doi: 10.1016/j.neuropharm.2011.11.008. Epub 2011 Nov 27.

PMID:
22138164
20.

Inhibiting glycine transporter-1 facilitates cocaine-cue extinction and attenuates reacquisition of cocaine-seeking behavior.

Nic Dhonnchadha BÁ, Pinard E, Alberati D, Wettstein JG, Spealman RD, Kantak KM.

Drug Alcohol Depend. 2012 Apr 1;122(1-2):119-26. doi: 10.1016/j.drugalcdep.2011.09.017. Epub 2011 Oct 10.

21.

fMRI fingerprint of unconditioned fear-like behavior in rats exposed to trimethylthiazoline.

Kessler MS, Debilly S, Schöppenthau S, Bielser T, Bruns A, Künnecke B, Kienlin Mv, Wettstein JG, Moreau JL, Risterucci C.

Eur Neuropsychopharmacol. 2012 Mar;22(3):222-30. doi: 10.1016/j.euroneuro.2011.07.011.

PMID:
21856130
22.

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.

Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Büttelmann B, Flament C, Diener C, Fischer C, Gatti S, Prinssen EP, Parrott N, Hoffmann G, Wettstein JG.

J Pharmacol Exp Ther. 2011 Nov;339(2):474-86. doi: 10.1124/jpet.111.185660. Epub 2011 Aug 17.

PMID:
21849627
23.

TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.

Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, Durkin S, Zbinden KG, Norcross R, Meyer CA, Metzler V, Chaboz S, Ozmen L, Trube G, Pouzet B, Bettler B, Caron MG, Wettstein JG, Hoener MC.

Proc Natl Acad Sci U S A. 2011 May 17;108(20):8485-90. doi: 10.1073/pnas.1103029108. Epub 2011 Apr 27.

24.

Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators.

Lundström L, Bissantz C, Beck J, Wettstein JG, Woltering TJ, Wichmann J, Gatti S.

Br J Pharmacol. 2011 Sep;164(2b):521-37. doi: 10.1111/j.1476-5381.2011.01409.x.

25.

Drug targets for cognitive enhancement in neuropsychiatric disorders.

Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG.

Pharmacol Biochem Behav. 2011 Aug;99(2):130-45. doi: 10.1016/j.pbb.2011.03.022. Epub 2011 Apr 1. Review.

PMID:
21463652
26.

Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Malherbe P, Knoflach F, Hernandez MC, Hoffmann T, Schnider P, Porter RH, Wettstein JG, Ballard TM, Spooren W, Steward L.

Br J Pharmacol. 2011 Feb;162(4):929-46. doi: 10.1111/j.1476-5381.2010.01096.x.

27.

Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential.

Alberati D, Moreau JL, Mory R, Pinard E, Wettstein JG.

Pharmacol Biochem Behav. 2010 Dec;97(2):185-91. doi: 10.1016/j.pbb.2010.07.016. Epub 2010 Aug 1.

28.

Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease.

Wulff K, Gatti S, Wettstein JG, Foster RG.

Nat Rev Neurosci. 2010 Aug;11(8):589-99. doi: 10.1038/nrn2868. Epub 2010 Jul 14. Review.

PMID:
20631712
29.

Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.

Pinard E, Alanine A, Alberati D, Bender M, Borroni E, Bourdeaux P, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Nettekoven M, Norcross RD, Puellmann B, Schmid P, Schmitt S, Stalder H, Wermuth R, Wettstein JG, Zimmerli D.

J Med Chem. 2010 Jun 24;53(12):4603-14. doi: 10.1021/jm100210p.

PMID:
20491477
31.

In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite.

Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein JG, Loetscher H, Chu T, Ebeling M, Paulson JC, Prinssen E, Brockhaus M.

Eur J Pharmacol. 2010 Feb 25;628(1-3):6-10. doi: 10.1016/j.ejphar.2009.11.020. Epub 2009 Nov 14.

32.

The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system.

Bradaia A, Trube G, Stalder H, Norcross RD, Ozmen L, Wettstein JG, Pinard A, Buchy D, Gassmann M, Hoener MC, Bettler B.

Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6. doi: 10.1073/pnas.0906522106. Epub 2009 Nov 5.

33.

Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.

Malherbe P, Kratzeisen C, Marcuz A, Zenner MT, Nettekoven MH, Ratni H, Wettstein JG, Bissantz C.

J Med Chem. 2009 Nov 26;52(22):7103-12. doi: 10.1021/jm900948q.

PMID:
19817444
34.

Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.

Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, Roche O, Rogers-Evans M, Wettstein JG, Moreau JL.

Br J Pharmacol. 2009 Apr;156(8):1326-41. doi: 10.1111/j.1476-5381.2009.00127.x.

35.

Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.

Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F.

Mol Pharmacol. 2009 Sep;76(3):618-31. doi: 10.1124/mol.109.055152. Epub 2009 Jun 19.

PMID:
19542319
36.

Rodent models of insomnia: a review of experimental procedures that induce sleep disturbances.

Revel FG, Gottowik J, Gatti S, Wettstein JG, Moreau JL.

Neurosci Biobehav Rev. 2009 Jun;33(6):874-99. doi: 10.1016/j.neubiorev.2009.03.002. Epub 2009 Mar 14. Review.

PMID:
19428498
37.

Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA.

Lundström L, Kuhn B, Beck J, Borroni E, Wettstein JG, Woltering TJ, Gatti S.

ChemMedChem. 2009 Jul;4(7):1086-94. doi: 10.1002/cmdc.200900028.

PMID:
19402024
38.

RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.

Ballard TM, Knoflach F, Prinssen E, Borroni E, Vivian JA, Basile J, Gasser R, Moreau JL, Wettstein JG, Buettelmann B, Knust H, Thomas AW, Trube G, Hernandez MC.

Psychopharmacology (Berl). 2009 Jan;202(1-3):207-23. doi: 10.1007/s00213-008-1357-7. Epub 2008 Oct 21.

PMID:
18936916
39.

Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors.

Malherbe P, Masciadri R, Norcross RD, Knoflach F, Kratzeisen C, Zenner MT, Kolb Y, Marcuz A, Huwyler J, Nakagawa T, Porter RH, Thomas AW, Wettstein JG, Sleight AJ, Spooren W, Prinssen EP.

Br J Pharmacol. 2008 Jun;154(4):797-811. doi: 10.1038/bjp.2008.135. Epub 2008 Apr 21.

40.

Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.

Nordquist RE, Steckler T, Wettstein JG, Mackie C, Spooren W.

Psychopharmacology (Berl). 2008 Aug;199(3):389-402. doi: 10.1007/s00213-008-1096-9. Epub 2008 Mar 6. Review.

PMID:
18322676
41.

Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains.

Malherbe P, Bissantz C, Marcuz A, Kratzeisen C, Zenner MT, Wettstein JG, Ratni H, Riemer C, Spooren W.

Mol Pharmacol. 2008 Jun;73(6):1736-50. doi: 10.1124/mol.107.042754. Epub 2008 Feb 28.

PMID:
18308898
42.

Trace amine-associated receptor 1 modulates dopaminergic activity.

Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, Bettler B, Wettstein JG, Borroni E, Moreau JL, Hoener MC.

J Pharmacol Exp Ther. 2008 Mar;324(3):948-56. Epub 2007 Dec 14.

PMID:
18083911
43.

The acoustic startle reflex in Sprague-Dawley rats is altered by permanent middle cerebral artery occlusion.

Maynard KI, Sukoff SJ, Ji Z, Wettstein JG, Black MD.

Brain Res. 2005 Jan 25;1032(1-2):44-9.

PMID:
15680940
44.

An electrophysiological model of spinal transmission deficits in mouse experimental autoimmune encephalomyelitis.

Hanak SE, Reilly EM, Wotanis J, Zhu B, Pulicicchio C, McMonagle-Strucko K, Wettstein JG, Black MD.

J Pharmacol Exp Ther. 2004 Jan;308(1):214-20. Epub 2003 Oct 17.

PMID:
14566007
45.

In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke.

Petty MA, Neumann-Haefelin C, Kalisch J, Sarhan S, Wettstein JG, Juretschke HP.

Eur J Pharmacol. 2003 Aug 1;474(1):53-62.

PMID:
12909195
47.

Comparative analysis of acute and chronic administration of haloperidol and clozapine using [3H] 2-deoxyglucose metabolic mapping.

Wotanis J, Hanak SE, Wettstein JG, Black MD.

Schizophr Res. 2003 Jun 1;61(2-3):195-205.

PMID:
12729871
48.

Statistical method for analysis of the disease curve in animals with experimental autoimmune encephalomyelitis.

Lee Y, Zhu B, Pulicicchio C, McMonagle-Strucko K, Wettstein JG, Cosmatos D.

J Biopharm Stat. 2003 Feb;13(1):141-58.

PMID:
12635908
49.

Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs.

Black MD, Simmonds J, Senyah Y, Wettstein JG.

Neuropharmacology. 2002 Mar;42(3):414-20.

PMID:
11897119
50.

Elements of cerebral microvascular ischaemia.

Petty MA, Wettstein JG.

Brain Res Brain Res Rev. 2001 Aug;36(1):23-34. Review.

PMID:
11516770

Supplemental Content

Loading ...
Support Center